Disc Medicine, Inc. (IRON)
NASDAQ (NMS) NASDAQ (NMS) Primary 
LSE 
Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript
Disc Medicine, Inc. ( IRON ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants John Quisel - CEO, President & Director Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Hello, everyone. Welcome to Jefferies London Healthcare Conference 2025.
Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference Transcript
Disc Medicine, Inc. ( IRON ) Stifel 2025 Healthcare Conference November 13, 2025 8:40 AM EST Company Participants Jonathan Yu - Chief Opearating Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division So we're going to go ahead and get started. I'm Steve Willey, one of the senior biotech analysts here at Stifel.
Disc Medicine: Forging Ahead In Hematology
Disc Medicine's strong financial position, with $489.9 million in cash and securities, ensures funding through 2028, reducing near-term financing risks. Lead asset Bitopertin shows promise in treating rare hematologic diseases, with a clear regulatory path and potential accelerated approval by H2 2025. Diversified pipeline includes DISC-0974 for anemia and DISC-3405 for iron overload, offering multiple paths to success in hematologic drug development.
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday.
